Talking to Patients about Cancer Treatment, Risk Factors, and Treatment Cessation during the COVID-19 Pandemic
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Sequencing Therapy for Patients with Lung Cancer
The NCCN Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer Panels have recently started identifying and recommending preferred systemic therapy regimens for patients with NSCLC and small cell lung cancer based on clinical data and experience; because these are recent recommendations,
Category
  • Breast Cancer
  • Colorectal Cancer
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Cardiovascular Health and Risk Management in Cancer Survivors
As the population of cancer survivors continues to grow, it becomes increasingly important for clinicians providing survivorship care to be informed about the increased risk for cardiovascular disease in this population, particularly as related to specific cancer treatment exposures and cardiovas
Category
  • Survivorship
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Evidence-Based Approaches to Smoking Cessation in Patients with Cancer
Providing care for patients with cancer who smoke poses unique challenges for oncology teams already managing a complex disease, and standardized guidance on effective smoking cessation interventions for patients with cancer is needed.
Category
  • Smoking Cessation
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Key Considerations in Adopting a Value-Based Payment Model
The shift from fee-for-service to value is well underway; there are at least 20 payment reform models currently in existence or proposed for adoption, from payers and/or physician groups.
Category
  • Best Practices
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Use of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Real-World Issues
Cancer immunotherapy is a rapidly growing and dynamic field, particularly for diseases such as lung cancer where immune checkpoint inhibitors are an important component of treatment.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Pharmacy Updates: Novel Treatments for Neuroendocrine Tumors
While there is a brand new treatment option for neuroendocrine tumors, it requires a wide array of practical guidance to be given safely and effectively.  Practitioners need to be well versed in patient eligibility, patient preparation for treatment, dosing, administration, and management of side effects.
Category
  • Neuroendocrine Tumors
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date September 28, 2020
NCCN Pharmacy Updates: Establishing a Place in Therapy for Biosimilars in Oncology
Clinical oncology pharmacists have the opportunity to provide education on biosimilars and be a part of the multi-disciplinary decision-making process for incorporating biosimilars into practice sites. In addition, pharmacists will need training on reporting post-marketing surveillance data regarding immunogenicity, product variability and drift of biosimilars as use becomes widespread.
Category
  • Biosimilars
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date October 28, 2020
Recorded Presentation from the NCCN Pharmacy Updates: Emerging Strategies for Pediatric Acute Lymphoblastic Leukemia Management
Pediatric ALL is a potentially curable malignancy and systemic therapy is the mainstay of treatment. Understanding the diagnosis, workup, and subsequent treatment of this disease will help clinicians play an important role in providing medication-related recommendations, supportive care, and patient counseling which can improve the outcomes and the quality of patient care.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer
Pharmacists should be aware of data on targeted therapy and immunotherapy for RCC and be able to make appropriate therapy recommendations. In addition, pharmacists play an important role in the management of toxicity of targeted therapy or immunotherapy and encouraging compliance for patients on targeted therapies for RCC.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages